Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Concord Medical Services ( (CCM) ) just unveiled an announcement.
On July 11, 2025, Concord Healthcare, a subsidiary of Concord Medical Services, successfully completed China’s first proton therapy treatment for choroidal malignant melanoma at the Guangzhou Concord Cancer Center. This innovative treatment offers a new eye-preserving option for patients, avoiding the traditional method of enucleation, and marks a significant advancement in oncology care within China.
Spark’s Take on CCM Stock
According to Spark, TipRanks’ AI Analyst, CCM is a Underperform.
The overall stock score for Concord Medical Services is significantly impacted by its poor financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively contribute to a low overall stock score, highlighting considerable risk.
To see Spark’s full report on CCM stock, click here.
More about Concord Medical Services
Concord Medical Services Holdings Limited is a healthcare provider specializing in oncology services, including cancer diagnosis, treatment, education, and prevention. The company operates a network of cancer hospitals and clinics across China, equipped with advanced technology like proton therapy systems, to enhance the quality and accessibility of cancer care.
Average Trading Volume: 30,192
Technical Sentiment Signal: Strong Sell
Current Market Cap: $22.79M
For a thorough assessment of CCM stock, go to TipRanks’ Stock Analysis page.